TARGETING METABOLIC DISEASE THROUGH ADVANCES IN ENDOCRINE RESEARCH

Metacrine is a biotech company developing innovative therapeutics for metabolic diseases. The company is led by an experienced management team and backed by leading institutional investors. Founded in 2015, Metacrine’s initial technology was licensed from the laboratory of Dr. Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute.

The current focus of the company is to develop novel therapeutics for significant metabolic diseases such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). There are over 30 million type 2 diabetics in the United States and despite numerous available drug classes, close to 50% of patients are unable to achieve target HbA1c levels and glucose control. Similarly, non-alcoholic steatohepatitis (NASH) is reaching epidemic proportions in the US and worldwide, with nearly 20% of Americans having some stage of fatty liver disease. Currently, there is no approved therapy for NASH.

Metacrine will leverage two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders.